TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00758485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (NaCl)
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Study: NCT03596593

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPANOM (identifying MSI status from ctDNA)
Description: SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
Study: NCT00713440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol
Description: OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days
Study: NCT01710176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose ifosfamide 14 g/m2, given in in 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
Study: NCT02271256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Intimate Apparel
Description: The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
Study: NCT03215836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy and Nasal Epithelium Brush Sampling
Description: After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy and Nasal Epithelium Brush Sampling
Description: After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy and Nasal Epithelium Brush Sampling
Description: After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy and Nasal Epithelium Brush Sampling
Description: After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
Study: NCT05865431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Oxide and Avobenzone
Description: Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
Study: NCT01805492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Description: Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
Study: NCT03528070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Subjects will be treated with tranilast
Study: NCT02593175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT04227015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA101
Description: CTA101 UCAR-T cell injection by intravenous infusion
Study: NCT04940429

Intervention type: DEVICE
Intervention: Neurofit
Description: This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.

Intervention type: DEVICE
Intervention: Neurofit
Description: This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric hepatic encephalopathy score
Description: During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric hepatic encephalopathy score
Description: During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
Study: NCT01426165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 8 grams over 4 or 8 hours depending on randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 8 grams over 4 or 8 hours depending on randomization
Study: NCT01982357

Intervention type: DEVICE
Intervention: Laser Speckle Imaging and Diffuse Optical Spectroscopy
Description: Laser Speckle Imaging and Diffuse Optical Spectroscopy
Study: NCT01981564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Express Intervention
Description: Asthma Express clinic visit for asthma education + nurse home visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education Control Group
Description: Asthma Express home nurse visits for asthma education
Study: NCT04531852

Intervention type: OTHER
Intervention: CALSTI - Complex Active Lifestyle Intervention
Description: A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance).

Intervention type: BEHAVIORAL
Intervention: SEMAI - Self-Management Intervention
Description: A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
Study: NCT01309633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5mg sunitinib with Cisplatin and Gemcitabine
Description: 1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
Study: NCT04777045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride
Description: Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
Study: NCT04335045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 100mg
Description: 1 x 100 mg PH100 oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 200mg
Description: 1 x 200 mg PH100 oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 400mg
Description: 2 x 200 mg PH100 oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 800mg
Description: 4 x 200 mg PH100 oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 1200mg
Description: 6 x 200 mg PH100 oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH100 1600mg
Description: 8 x 200 mg PH100 oral capsules
Study: NCT03404570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine HCl
Description: Investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing no active drug.
Study: NCT04307004

Intervention type: OTHER
Group type: OTHER
Intervention: Unattended blood pressure measurement
Description: Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.

Intervention type: OTHER
Group type: OTHER
Intervention: Attended blood pressure measurement
Description: Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.

Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory blood pressure monitoring
Description: Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.

Intervention type: OTHER
Group type: OTHER
Intervention: Home blood pressure monitoring
Description: Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
Study: NCT05400434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Description: PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Description: PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Description: PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Description: PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Helpers (NH)
Description: Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Helpers (NH)
Description: Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
Study: NCT01753687

Intervention type: OTHER
Group type: OTHER
Intervention: Ocular scattering of the tear film

Intervention type: OTHER
Group type: OTHER
Intervention: Optical Coherence Tomography (OCT)
Description: Tear film thickness as measured with OCT

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of tear film osmolarity
Study: NCT04745611

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: 3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
Study: NCT02295592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSTstarr+
Description: TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPH
Description: PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
Study: NCT02020538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-chloride perioperative intravenous fluid strategy
Description: The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
Study: NCT03175133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercise
Description: Strengthening exercises performed with physical therapist.
Study: NCT02020538

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-chloride perioperative intravenous fluid strategy
Study: NCT01839214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-201 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 160mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00908154

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets to match GSK1014802

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets to match GSK1014802

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets to match GSK1014802

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Tablets to match GSK1014802

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Sodium channel blocker

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Sodium channel blocker

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Sodium channel blocker

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802
Description: Sodium channel blocker
Study: NCT03612791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: * Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: * Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: * Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: * Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted.
Study: NCT03728972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IVPB every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IVPB every 3 weeks